DexCom (NASDAQ:DXCM) Given Buy Rating at TD Cowen

DexCom (NASDAQ:DXCM - Get Free Report)'s stock had its "buy" rating restated by equities researchers at TD Cowen in a research report issued on Friday, September 18th, Benzinga reports. They presently have a $95.00 price objective on the medical device company's stock. TD Cowen's price target suggests a potential upside of 9.67% from the company's current price.

Several other research analysts have also recently weighed in on the stock. Robert W. Baird set a $105.00 price objective on shares of DexCom in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $65.00 to $82.00 and gave the stock a "neutral" rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a research report on Tuesday, June 23rd. They issued a "buy" rating and a $86.00 price objective for the company. Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Sunday, September 6th. Finally, UBS Group set a $96.00 price objective on shares of DexCom and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $89.08.

DexCom Trading Down 1.0%

DXCM stock traded down $0.85 during trading on Friday, hitting $86.62. The company had a trading volume of 1,875,538 shares, compared to its average volume of 5,116,766. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $85.16 and a 200-day moving average price of $73.77. DexCom has a 12 month low of $54.11 and a 12 month high of $92.59. The stock has a market cap of $32.69 billion, a price-to-earnings ratio of 34.24, a PEG ratio of 1.50 and a beta of 1.42.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion during the quarter, compared to analysts' expectations of $1.29 billion. During the same quarter in the previous year, the company posted $0.48 EPS. DexCom's revenue was up 13.1% on a year-over-year basis. As a group, analysts predict that DexCom will post 2.64 earnings per share for the current year.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the sale, the director owned 48,852 shares of the company's stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president directly owned 146,828 shares of the company's stock, valued at $12,226,367.56. This represents a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,504 shares of company stock worth $5,651,332. Corporate insiders own 0.28% of the company's stock.

Hedge Funds Weigh In On DexCom

Institutional investors and hedge funds have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB grew its position in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company's stock valued at $77,000 after buying an additional 153 shares during the period. V Square Quantitative Management LLC grew its position in DexCom by 1.8% during the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after buying an additional 172 shares during the period. Essex Financial Services Inc. lifted its holdings in DexCom by 5.7% during the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after purchasing an additional 175 shares in the last quarter. Gabelli Funds LLC lifted its holdings in DexCom by 0.4% during the fourth quarter. Gabelli Funds LLC now owns 50,200 shares of the medical device company's stock valued at $3,332,000 after purchasing an additional 200 shares in the last quarter. Finally, One Wealth Map LLC lifted its holdings in DexCom by 5.6% during the first quarter. One Wealth Map LLC now owns 4,900 shares of the medical device company's stock valued at $301,000 after purchasing an additional 261 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.